XERS

Xeris Biopharma Holdings, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website xerispharma.com
Employees(FY) 355
ISIN US98422E1038

Performance

+2.65%

+15.95%

+17.91%

+63.85%

+48.51%

YTD

+73.63%

Profile

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Advanced Technical Analysis

Technical Analysis of XERS 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 76 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of XERS

Stock Rank

Recent News & Updates

2024-11-26 07:00
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference(Business Wire)
2024-11-25 18:00
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference(Businesswire)
2024-11-17 07:57
Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long(Simply Wall St.)
2024-11-11 07:25
Piper Sandler Downgrades Xeris Biopharma to Neutral From Overweight, $3 Price Target(MT Newswires)
2024-11-08 13:06
Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...(Yahoo Finance)
2024-11-08 07:00
Xeris Biopharma Reports Third Quarter 2024 Financial Results(Business Wire)
2024-11-07 20:30
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates(Yahoo Finance)
2024-11-07 19:10
Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-11-07 18:10
Xeris Biopharma: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-07 18:00
Xeris Biopharma Reports Third Quarter 2024 Financial Results(Businesswire)
2024-10-30 20:00
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024(Businesswire)
2024-10-09 11:38
Several Insiders Invested In Xeris Biopharma Holdings Flagging Positive News(Simply Wall St.)
2024-10-04 16:05
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Business Wire)
2024-10-04 04:05
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Businesswire)
2024-09-25 06:22
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?(Zacks)
2024-09-12 11:27
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) most popular amongst individual investors who own 53% of the shares, institutions hold 43%(Simply Wall St.)
2024-08-22 07:00
Xeris to Participate in Upcoming Investor Conferences(Business Wire)
2024-08-21 19:00
Xeris to Participate in Upcoming Investor Conferences(Businesswire)
2024-08-08 07:00
Xeris Biopharma Reports Second Quarter 2024 Financial Results(Business Wire)
2024-08-07 20:25
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-08-07 19:30
Xeris Biopharma: Q2 Earnings Snapshot(Yahoo Finance)
2024-08-07 19:00
Xeris Biopharma Reports Second Quarter 2024 Financial Results(Businesswire)
2024-07-31 22:01
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know(Yahoo Finance)
2024-07-24 19:00
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024(Businesswire)
2024-07-23 21:55
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?(Yahoo Finance)
2024-07-07 19:00
Xeris Biopharma Announces CEO Succession Plan(Businesswire)
2024-07-03 01:05
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Businesswire)
2024-06-02 19:00
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushings Syndrome Patients at ENDO 2024(Businesswire)
2024-05-29 19:30
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)(Yahoo Finance)
2024-05-29 19:00
Xeris to Participate in the Jefferies Global Healthcare Conference(Businesswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.